The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test.
The firm anticipates completing the study in about 18 months and then applying for US Food and Drug Administration clearance for its multimodal platform and assays.
The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.
